These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10156501)

  • 41. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.
    Atella V
    Health Policy; 2000 Jan; 50(3):197-218. PubMed ID: 10827308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
    Savage P; Mahmoud S; Patel Y; Kantarjian H
    J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The German experience in reference pricing.
    Giuliani G; Selke G; Garattini L
    Health Policy; 1998 Apr; 44(1):73-85. PubMed ID: 10180203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
    Glynn D
    Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 49. Controlling the cost of prescription drugs.
    White JR
    Health Prog; 1992 Mar; 73(2):12-4, 25. PubMed ID: 10116498
    [No Abstract]   [Full Text] [Related]  

  • 50. The drug bargaining game: pharmaceutical regulation in Australia.
    Wright DJ
    J Health Econ; 2004 Jul; 23(4):785-813. PubMed ID: 15587698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher Drug Prices from Anticompetitive Conduct: Three Case Studies.
    Carrier MA
    J Leg Med; 2019; 39(2):151-167. PubMed ID: 31503532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescription drug manufacturers get warning on prices.
    Margolis RE
    Healthspan; 1993 Mar; 10(3):19-20. PubMed ID: 10125344
    [No Abstract]   [Full Text] [Related]  

  • 54. These doctor's mission: keeping drug costs down.
    Guglielmo WJ
    Med Econ; 2001 Apr; 78(8):108-10, 113-6. PubMed ID: 11386066
    [No Abstract]   [Full Text] [Related]  

  • 55. [The AMNOG and its consequences].
    Dingermann T
    Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proposal To Use VA Price As a Benchmark Is off the Mark.
    Kirkner RM
    Manag Care; 2016 Dec; 25(12):14-15. PubMed ID: 28121548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 58. Which Drug Prices Should Medicare Negotiate? A "Too Little" or "Too Late" Approach.
    Bach PB
    N Engl J Med; 2019 Nov; 381(22):2084-2086. PubMed ID: 31774952
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK.
    Borrell JR
    Pharmacoeconomics; 1999 Mar; 15(3):291-303. PubMed ID: 10537436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring the rise in American pharmaceutical prices.
    Marwaha A
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.